A post hoc analysis was performed of the placebo group ( n = 2061 ) of the EVEREST trial , which enrolled patients within 48 hours of admission for worsening HF with an ejection fraction ( EF ) 40 % and an SBP 90 mm Hg , for a median follow-up of 9.9 months .
